Le Lézard
Classified in: Health, Business
Subject: ESG

Cavulus CEO's 2019 Prediction About Medicare Advantage Competition Rings True


PITTSBURGH, Pa., Feb. 8, 2022 /PRNewswire/ -- In 2019, Patrick Phillips, CEO of Cavulus, a preeminent Medicare Advantage (MA) technology firm, warned industry leaders that new start-ups would soon disrupt the status quo of the fast-growing industry's dominant players.

"Many recent entries in the MA market are tech-backed startups with an agile, grass-roots approach," said Phillips.

That prediction has manifested itself in the current Annual Election Period (AEP) results released last month.

A January Business Insider article noted that "health-insurance upstarts are stealing members from dominant players like Humana in the red-hot market for older Americans."

Bruce Broussard, President & CEO of the $83 billion Humana Insurance Company (5th largest health insurer in terms of membership) acknowledged that aggressive competitors have cut his company's growth projections by 50% which caused Humana stock to plunge - "the most intraday in 13 years" according to Bloomberg.

As Phillips points out: "Many recent entrants in the MA market are tech-backed start-ups who bring an agile, grass-roots approach to marketing with high-touch customer service that can be cumbersome for a number of dominant insurers who serve millions of members."

Phillips also believes "there's often a reluctance to change" among legacy insurers which may continue to impact their growth. "Our firm has been exclusively serving the MA market for 16 years," he said, "and we're still surprised how often we encounter antiquated workflows, technology and paper processing still going on with many of the larger health insurers."

Cavulus works with established and new MA organizations, and Phillips has observed "a nimbleness characteristic of many new smaller insurers" plus "an adaptability that may ultimately position them to better respond to the increasing waves of Medicare eligible individuals." However, he does expect legacy plans will be forced to re-evaluate their strategies noting that last week Humana executives quickly announced they "will invest in automation to run their business more efficiently."

ABOUT CAVULUS - Cavulus is a technology-driven specialist in Medicare Advantage insurance solutions. The Cavulus Cloud-based Medicare Advantage Platform (Cavulus MAPtm) unifies marketing, sales, and enrollment operations, and is utilized by many of America's top insurers, including several BlueCross/ BlueShield companies, UPMC Health Plan, Johns Hopkins, Lumeris and United Healthcare. For details visit: www.cavulus.com.

Media Inquiries: 800-760-6915
Email: [email protected]

SOURCE Cavulus


These press releases may also interest you

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...

at 16:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As...

at 16:10
ENDRA Life Sciences Inc. , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update. Highlights from the fourth quarter of 2023...

at 16:08
Today, MPOWERHealth, a pioneer in the field of intraoperative neuromonitoring (IONM), announced the strategic acquisition of Assure Neuromonitoring's operations in pivotal markets, marking a significant step in expanding its best-in-class...

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....



News published on and distributed by: